Status:

UNKNOWN

Precision Dosing of Busulfan in Children Undergoing HSCT

Lead Sponsor:

University Hospital, Geneva

Conditions:

Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation

Eligibility:

All Genders

Up to 18 years

Phase:

NA

Brief Summary

The objective of this clinical trial is to evaluate the personalization the conditioning regimen prior to the hematopoietic stem cell transplant (HSCT) in children and adolescents, to improve HSCT eff...

Detailed Description

Participants will be randomly assigned (1:1 ratio, stratified by conditioning regimen - the presence of fludarabine) to receive their first dose of busulfan according to: 1. the most performing metho...

Eligibility Criteria

Inclusion

  • Patients must be aged from 0-18 years old on entry to the study;
  • Clinical indication of allogeneic or autologous hematopoietic stem cell transplantation;
  • The conditioning protocol must include IV Bu formulations, Busulfex® (Otsuka Pharmaceutical), Busilvex® (Pierre Fabre Pharma) or other European Medicines Agency (EMA) or Food and Drugs Administration (FDA) approved generic formulations regardless of the administration schedule (q6h, q12h, or q24h)
  • The expected length of time from recruitment to starting the conditioning regimen must be superior to 10 days;
  • Informed written consent to participate in the study signed by the participant/parent

Exclusion

  • • At least one of the drugs listed below scheduled to be administered in the Bu administration days up to 24h after the last dose of Bu, whenever a washout is not possible:
  • Metronidazol (required washout: 7 days)
  • Nalidixic acid (required washout: 7 days)
  • Phenytoin (required washout: 21 days)
  • Itraconazole (required washout: 14 days)
  • Ketoconazole (required washout: 7 days)
  • Voriconazole (required washout: 7 days)
  • Deferasirox (required washout: 7 days)

Key Trial Info

Start Date :

June 15 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2025

Estimated Enrollment :

260 Patients enrolled

Trial Details

Trial ID

NCT04822532

Start Date

June 15 2021

End Date

June 1 2025

Last Update

August 2 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpitaux Universitaires de Genève

Geneva, Switzerland